Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease

NCT01696474 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Refractory Cold Agglutinin Disease

Interventions

DRUG: Bortezomib

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto